An mRNA nasal spray capable of transforming the nasal cavities into a small factory of drugs for the central nervous system, which have been shown to improve learning and memory and protect against the symptoms of Alzheimer’s. It is the result of research by the University of Sydney and published in the journal Advanced Science: an approach that uses the same mRna technological platform developed for vaccines against Covid-19 to bypass the blood-brain barrier that separates the brain from the bloodstream, one of the main obstacles in the pharmacological treatment of neurodegenerative diseases.
The mRNA platform
The project is based on mRNA encapsulated in lipid nanoparticles. A technology already clinically validated with vaccines, which in this case does not instruct cells to produce antigens to stimulate an immune response, but conveys the genetic instructions to synthesize a protein naturally present in our body, known as brain neurotrophic factor, or Bdnf. It is a fundamental molecule for the survival of neurons, synaptic plasticity and the formation of memories, the levels of which tend to decline physiologically with aging, and are markedly deficient in patients suffering from Alzheimer’s disease.
“The success of mRna vaccines has demonstrated that these systems can deliver genetic instructions to cells in a safe way,” explains Maria Bergamasco, researcher at the School of Life and Environmental Sciences at the University of Sydney and first author of the study. “We wanted to see if it was possible to adapt that technology to deliver beneficial proteins into the brain in a completely non-invasive way.”
Bypass the blood brain barrier
The choice to administer the new therapy in the form of a nasal spray made it possible to overcome one of the main limitations in the treatment of neurological diseases: the blood-brain barrier, a protective structure that prevents harmful molecules, and almost all drugs circulating in the blood, from reaching the brain tissue. Intranasal administration exploits the direct anatomical connections between the nasal cavity and the brain, allowing the active ingredient to be conveyed to the central nervous system without resorting to surgical interventions or invasive injections into the spinal cord.
For now, the preparation has been tested on an animal model. And in behavioral tests aimed at evaluating working memory, spatial orientation and object recognition, elderly mice treated with nasal drops recovered cognitive performance similar to that of young specimens. The tissue analysis also highlighted an increase in neurogenesis, or the formation of new neurons, within the hippocampus, the brain area crucial for learning.
The research group then tested the therapy on the 5XFAD mouse model, animals genetically modified to develop a rapid form of Alzheimer’s disease, which normally present visible brain changes as early as two months of life and a cognitive decline evident around four months. By administering the treatment twice a week starting from two months of age, the animals did not show any cognitive deterioration beyond the fourth month of life.
An interesting aspect that emerged from the study concerns the mechanism of action: the improvement observed in mice occurred without any reduction in amyloid plaques, the protein aggregates characteristic of Alzheimer’s against which many of the therapies under development for this disease are aimed.
According to Greg Neely, professor of functional genomics at the University of Sydney, this aspect suggests that the therapy could complement, rather than replace, current anti-amyloid drugs: “Just under a third of Alzheimer’s patients have extensive plaques but do not develop dementia, and these people show naturally higher levels of Bdnf – explains Neely – Our approach does not work by clearing the plaques, but by directly supporting the health, survival and connectivity of neurons”.
Towards clinical trials
Despite the absence of significant side effects in the treated animals, the authors urge caution for now, remembering that the study is still in the preclinical phase. The anatomy of human nasal cavities is very different from that of rodents, a factor that will require careful evaluation of the real effectiveness of the molecule in humans.
The next step will be to complete the long-term safety studies required by regulatory authorities. Since the individual components of the formulation – both the lipid envelope and the mRNA structure – have already been extensively tested on humans in previous clinical trials, the Australian group aims to reduce development times, with the aim of starting the first clinical trials on patients within the next two years. If the results were to be confirmed, the platform could find application not only in neurodegenerative diseases, but also in post-stroke recovery, head trauma and in combating age-related cognitive decline.